ScreenerHero

ATORX Alligator Bioscience AB (publ)

STO · SE · Healthcare · Biotechnology · alligatorbioscience.se
0.0173SEK+0.58%Mkt Cap: 5.90M $P/E: —

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.90M USD
Enterprise Value2.31M USD
Revenue (TTM)65.14K USD
Gross Profit-5.95M USD
Net Income (TTM)-4.91M USD
Revenue/Share0.0020 SEK
Last Price0.0173 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0024173637
Valuation
P/E (Trailing)—
P/E (Forward)-0.22
PEG—
EV/EBITDA-0.22
EV/Revenue35.41
P/S90.12
P/B3.44
EPS (TTM)-0.60
EPS (Forward)-0.08
52W Range
0.01600% of range4.750
52W High4.750 SEK
52W Low0.0160 SEK
Profitability
Gross Margin0.00%
Oper. Margin-14501.20%
EBITDA Margin0.00%
Profit Margin-9990.27%
ROE-748.65%
ROA-46.43%
Growth
Revenue Growth180.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.92M USD
CapEx (TTM)139.75K USD
FCF Margin-16787.11%
FCF Yield-185.20%
Net Debt1.27M USD
Net Debt/EBITDA-0.12
Balance Sheet
Debt/Equity6.29
Current Ratio0.58
Quick Ratio0.50
Book Value/Sh0.0050 SEK
Cash/Share0.03 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateApr 7, 2025
Analyst Consensus
Rating—
Target (Mean)0.0560 SEK
Upside (mean)+223.7%
Target Range0.0560 SEK – 0.0560 SEK
# Analysts1
Ownership
Shares Out.3.57B
Float613.86M
Insiders1.65%
Institutions2.88%
Technical
SMA 500.0281 (-38.5%)
SMA 2000.1612 (-89.3%)
Beta1.17
S&P 52W Chg16.45%
Avg Vol (30d)15.65M
Avg Vol (10d)10.63M
Technical Indicators
RSI (14)24.8
MACD-0.0055
MACD Signal-0.0067
MACD Hist.+0.0012
BB Upper0.0250 SEK
BB Middle0.0210 SEK
BB Lower0.0170 SEK
BB Width38.04%
ATR (14)0.0031 SEK
Vol Ratio (20d)1.05x